CTLA4 and cancer: Nivolumab or pembrolizumab (targeting programmed death 1 [PD-1] checkpoint monoclonal antibody) and ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint monoclonal antibody) have become standard immune therapy for patients with advanced cancers.